Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Business Ethics
Contact us
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2011
Press release archive
Webcast and presentation
DRUG CANDIDATES
ELND005 - Alzheimer's disease
TT301/302 - inflammation
TT401/402 - diabetes
PRODUCT PIPELINE
View Transition's product pipeline
LATEST NEWS
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401 - Dec 12, 2011
© 2011 Transition Therapeutics Inc.
